David Arkowitz
Director/Board Member chez KINETA, INC.
Fortune : 141 210 $ au 31/03/2024
Profil
David A.
Arkowitz is currently the Director at Yumanity, Inc. and an Independent Director at Kineta, Inc. He previously held positions as a Director at ImpactRx, Inc., Aegerion Pharmaceuticals, Inc., Merck-Medco Managed Care LLC, Proteostasis Therapeutics, Inc., and F-Star Therapeutics, Inc. (United States).
He also served as the VP & Controller-Research & Development Division at Merck & Co., Inc., Chief Financial Officer & Treasurer at Idenix Pharmaceuticals LLC, Chief Financial Officer & General Manager at Mascoma Corp., Chief Financial & Accounting Officer at Flexion Therapeutics, Inc., and Chief Operating & Financial Officer at Visterra, Inc. Additionally, he was the Vice President-Finance & Business Development at Merck Frosst Canada Ltd.
and Controller at Merck Research Laboratories Massachusetts LLC.
Mr. Arkowitz is a graduate of Brandeis University with an undergraduate degree and holds an MBA from Columbia Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SERES THERAPEUTICS INC
0,12% | 16/02/2024 | 182 442 ( 0,12% ) | 141 210 $ | 31/03/2024 |
KINETA, INC.
-.--% | 17/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de David Arkowitz
| Sociétés | Poste | Début |
|---|---|---|
| KINETA, INC. | Director/Board Member | 19/12/2022 |
Yumanity, Inc.
 Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Director/Board Member | - |
Anciens postes connus de David Arkowitz
| Sociétés | Poste | Fin |
|---|---|---|
| SERES THERAPEUTICS, INC. | Director of Finance/CFO | 15/03/2024 |
| F-STAR THERAPEUTICS, INC. | Director/Board Member | 08/03/2023 |
| FLEXION THERAPEUTICS, INC. | Director of Finance/CFO | 31/05/2021 |
| VISTERRA INC | Director of Finance/CFO | 01/05/2018 |
Mascoma Corp.
 Mascoma Corp. BiotechnologyHealth Technology Mascoma Corp. develops technology for abundant biomass conversion. The firm operates through its bioprocessing technology platform, develops bioengineered yeasts and other microorganisms. It also designs and manufactures equipment that processes cellulosic biomass for further biological or chemical conversion. The company was founded by Lee R. Lynd, Charles E. Wyman and Robert J. Johnsen in 2005 and is headquartered in Waltham, MA. | Director of Finance/CFO | 01/09/2013 |
Formation de David Arkowitz
| Brandeis University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| SERES THERAPEUTICS, INC. | Health Technology |
| KINETA, INC. | Health Technology |
| Entreprise privées | 15 |
|---|---|
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
ImpactRx, Inc.
 ImpactRx, Inc. Miscellaneous Commercial ServicesCommercial Services ImpactRx, Inc. was provided health-care sector custom research and promotional consultancy services. The company was founded by Lawrence G. Miller, Terry Overton and Gerald J. Gallivan in 2000 and was headquartered in Horsham, PA. | Commercial Services |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Mascoma Corp.
Mascoma Corp. BiotechnologyHealth Technology Mascoma Corp. develops technology for abundant biomass conversion. The firm operates through its bioprocessing technology platform, develops bioengineered yeasts and other microorganisms. It also designs and manufactures equipment that processes cellulosic biomass for further biological or chemical conversion. The company was founded by Lee R. Lynd, Charles E. Wyman and Robert J. Johnsen in 2005 and is headquartered in Waltham, MA. | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Visterra, Inc.
 Visterra, Inc. Pharmaceuticals: MajorHealth Technology Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA. | Health Technology |
Merck-Medco Managed Care LLC
 Merck-Medco Managed Care LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck-Medco Managed Care LLC discovers, develops, and markets a broad range of human and animal health products. The private company is based in Whitehouse Station, NJ. | Health Technology |
Merck Frosst Canada Ltd.
 Merck Frosst Canada Ltd. Pharmaceuticals: MajorHealth Technology Merck Frosst Canada Ltd. is a Canadian pharmaceutical company that has been inventing medicines and vaccines for over 130 years. The company is based in Kirkland, Canada. The company's mission is to save and improve lives by bringing forward solutions for some of the world's most challenging diseases. | Health Technology |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
F-Star Therapeutics, Inc. (United States)
 F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Health Technology |
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Yumanity Therapeutics, Inc.
 Yumanity Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA. | Health Technology |
